Patients with 3 or more adverse pregnancy outcomes had lower odds of postpartum contraceptive use in a PRAMS analysis of 222,412 individuals.
News|Articles|February 18, 2026 (Updated: February 18, 2026)
ACOG updates maternal immunization guidance
Author(s)Joshua Fitch, Senior Editor
Fact checked by: Benjamin P. Saylor
The updated Committee Statement reaffirmed the safety and benefits of influenza, COVID-19, Tdap, and RSV vaccines during pregnancy while addressing misinformation and disparities.
Advertisement
Advertisement
The American College of Obstetricians & Gynecologists (ACOG) released updated guidance on maternal immunizations, reinforcing the importance of routine vaccination during pregnancy to protect both pregnant individuals and their infants. The Committee Statement was published February 18, 2026, in Obstetrics & Gynecology.1,2
Related to this article
Real-world data show maternal RSVpreF vaccination was 82% effective against infant RSV LRTI hospitalization through 3 months.
Peter Hsin, BS, discusses a meta-analysis linking perioperative ketamine to lower early postpartum depressive symptoms after cesarean delivery.
The FDA granted accelerated approval to Voceryq to reduce papilloma excision surgeries in adults with recurrent respiratory papillomatosis.
Neither maternal MOUD dose nor umbilical cord opioid levels were associated with neonatal opioid withdrawal syndrome severity.
ACOG advises against GLP-1 receptor agonists in pregnancy and recommends considering discontinuation 1 to 2 months before conception.
Risk factors cast a wide net in preeclampsia prediction, but biomarkers could add precision, according to Dallas Reed, MD.
Joint guidance from the AHA, AAP, ACOG, and SMFM organizes cardiovascular prevention for girls and women around 4 female life stages.
Advertisement
Advertisement